# US 8,278,308 B2 · Diketopiperazine salts for drug delivery and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,308 B2
- Document ID: US8278308B2
- Status: Granted
- Kind: B2
- Application number: 12/886,226
- Filed: 2010-09-20
- Published: 2011-01-13
- Granted: 2012-10-02
- Earliest claimed: 2004-08-23
- Assignees: MannKind Corporation
- Inventors: Andrea Leone-Bay; Destardi Moye-Sherman; Bryan R. Wilson
- Web page: https://patentgrep.com/patent/US8278308B2

## CPC

- A61K 38/28: Insulins
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1682: {Processes}
- A61K 9/4858: {Organic compounds}
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 241/02: not condensed with other rings
- C07D 241/08: with oxygen atoms directly attached to ring carbon atoms
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.

## Claims

### Claim 1

A method for delivery of a biologically active agent comprising:
administering to a patient in need of treatment therewith an effective amount of a biologically active agent in the form of microparticles, said microparticles comprising a pharmaceutically acceptable salt of a diketopiperazine and the biologically active agent;
wherein said microparticles release said biologically active agent upon administration; and
wherein said pharmaceutically acceptable salt of the diketopiperazine has the structure according to Formula 1:
wherein Formula 1 is a diketopiperazine selected from the following compounds:
3,6-di(4-aminobutyl)-2,5-diketopiperazine,
3,6-di(succinyl-4-aminobutyl)-2,5-diketopiperazine,
3,6-di(maleyl-4-aminobutyl)-2,5-diketopiperazine,
3,6-di(citraconyl-4-aminobutyl)-2,5-diketopiperazine,
3,6-di(glutaryl-4-aminobutyl)-2,5-diketopiperazine,
3,6-di(malonyl-4-aminobutyl)-2,5-diketopiperazine,
3,6-di(oxalyl-4-aminobutyl)-2,5-diketopiperazine, and
3,6-di(fumaryl-4-aminobutyl)-2,5-diketopiperazine; and
said salt further comprises at least one cation.

### Claim 2 (depends on 1)

The method of claim 1 wherein said biologically active agent is selected from the group consisting of hormones, anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics, antivirals, antisense, antigens, antibodies and active fragments and analogues thereof.

### Claim 3 (depends on 1)

The method of claim 1 wherein said biologically active agent is selected from the group consisting of insulin, cannabinoids, heparins, calcitonin, felbamate, parathyroid hormone and fragments thereof, growth hormone, erythropoietin, glucagonlike peptide-1, somatotrophin-releasing hormone, follicle stimulating hormone, cromolyn, adiponectin, RNAse, ghrelin, zidovudine, didanosine, tetrahydrocannabinol, atropine, granulocytes colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase and Argatroban.

### Claim 4 (depends on 1)

The method of claim 1 wherein said cation is selected from the group consisting of sodium, potassium, calcium, lithium, triethylamine, butylamine, diethanolamine and triethanolamine.

### Claim 5 (depends on 1)

The method of claim 1 wherein R1 or R2 comprise X-4-aminobutyl and wherein X is selected from the group consisting of succinate, glutarate, maleate and fumarate.

### Claim 6 (depends on 5)

The method of claim 5 wherein X is fumarate.

### Claim 7 (depends on 1)

The method of claim 1 wherein said microparticles have a diameter between about 0.5 microns and about ten microns.

### Claim 8 (depends on 1)

The method of claim 1 wherein said microparticles release said biologically active agent upon contact with a biological fluid.

### Claim 9 (depends on 1)

The method of claim 1 wherein said delivery is to the pulmonary system.

### Claim 10 (depends on 9)

The method of claim 9 wherein said microparticles release said biologically active agent in the pulmonary system.

### Claim 11 (depends on 8)

The method of claim 8, wherein the biologically active agent is absorbed into the systemic blood circulation.

### Claim 12 (depends on 1)

The method of claim 1 wherein said active agent-containing microparticles are formed by spray drying a solution of said pharmaceutically acceptable salt of a heterocyclic compound and said biologically active agent.

### Claim 13 (depends on 3)

The method according to claim 3, wherein said active agent is insulin.

### Claim 14 (depends on 4)

The method according to claim 4, wherein said cation is sodium.
